Literature DB >> 19608273

Multiple mechanisms induce ectopic expression of LYL1 in subsets of T-ALL cell lines.

Stefan Nagel1, Letizia Venturini, Corinna Meyer, Maren Kaufmann, Michaela Scherr, Hans G Drexler, Roderick A F MacLeod.   

Abstract

Basic helix-loop-helix (bHLH) transcription factors are essential for lymphocytic differentiation. Here, we have analyzed the complete bHLH family in T-cell acute lymphoblastic leukemia cell lines by expression profiling. Differential expression was detected for BHLHB2, HES1, HES4, HEY1, ID1, ID2, ID3, LYL1 and TAL1, highlighting dysregulation of family members with inhibitory activity. Subsequently we focused on the mechanisms responsible for aberrant expression of LYL1 in comparison to TAL1. Quantitative genomic PCR indicated microdeletions upstream of both, TAL1 and LYL1, targeting STIL/SIL and TRMT1, respectively. Additionally, one LYL1-expressing cell line exhibited amplification of TRMT1. While deletion of STIL correlated with expression of the STIL-TAL1 fusion transcript, no TRMT-LYL1 fusion transcripts were detected in parallel with genomic rearrangements thereof. Sequence analysis of the LYL1 promoter region revealed potential binding sites for transcription factors HOXA10, LMO2 and NKX2-5. Overexpression analysis, reporter gene assays and chromatin immuno-precipitation confirmed their activating impact on LYL1 expression. In conclusion, we identified multiple mechanisms which activate LYL1 in leukemic cells, including structural genomic alterations, namely microdeletion or amplification, together with the involvement of prominent oncogenic transcription factors. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19608273     DOI: 10.1016/j.leukres.2009.06.020

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

1.  The expansion of T-cells and hematopoietic progenitors as a result of overexpression of the lymphoblastic leukemia gene, Lyl1 can support leukemia formation.

Authors:  Georgi L Lukov; Lara Rossi; George P Souroullas; Rui Mao; Margaret A Goodell
Journal:  Leuk Res       Date:  2010-08-11       Impact factor: 3.156

2.  Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines.

Authors:  Stefan Nagel; Letizia Venturini; Victor E Marquez; Corinna Meyer; Maren Kaufmann; Michaela Scherr; Roderick Af MacLeod; Hans G Drexler
Journal:  Mol Cancer       Date:  2010-06-17       Impact factor: 27.401

3.  LYL1 degradation by the proteasome is directed by a N-terminal PEST rich site in a phosphorylation-independent manner.

Authors:  Georgi L Lukov; Margaret A Goodell
Journal:  PLoS One       Date:  2010-09-10       Impact factor: 3.240

4.  3,3'-Diindolylmethane induces G1 arrest and apoptosis in human acute T-cell lymphoblastic leukemia cells.

Authors:  Lyndsey E Shorey; Amanda M Hagman; David E Williams; Emily Ho; Roderick H Dashwood; Abby D Benninghoff
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

5.  SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells.

Authors:  Bastien Gerby; Cedric S Tremblay; Mathieu Tremblay; Shanti Rojas-Sutterlin; Sabine Herblot; Josée Hébert; Guy Sauvageau; Sébastien Lemieux; Eric Lécuyer; Diogo F T Veiga; Trang Hoang
Journal:  PLoS Genet       Date:  2014-12-18       Impact factor: 5.917

6.  Transcriptome Analyses Identify an RNA Binding Protein Related Prognostic Model for Clear Cell Renal Cell Carcinoma.

Authors:  Yue Wu; Xian Wei; Huan Feng; Bintao Hu; Bo Liu; Yang Luan; Yajun Ruan; Xiaming Liu; Zhuo Liu; Shaogang Wang; Jihong Liu; Tao Wang
Journal:  Front Genet       Date:  2021-01-07       Impact factor: 4.599

7.  Transcriptional activation of prostate specific homeobox gene NKX3-1 in subsets of T-cell lymphoblastic leukemia (T-ALL).

Authors:  Stefan Nagel; Stefan Ehrentraut; Jürgen Tomasch; Stefan Lienenklaus; Björn Schneider; Robert Geffers; Corinna Meyer; Maren Kaufmann; Hans G Drexler; Roderick A F MacLeod
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

8.  In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL.

Authors:  S Laukkanen; T Grönroos; P Pölönen; H Kuusanmäki; J Mehtonen; J Cloos; G Ossenkoppele; B Gjertsen; B Øystein; C Heckman; M Heinäniemi; M Kontro; O Lohi
Journal:  Blood Cancer J       Date:  2017-09-08       Impact factor: 11.037

9.  Genomic profile of a squamous cell carcinoma ex pleomorphic adenoma compared to a head and neck squamous cell carcinoma.

Authors:  Fernanda Viviane Mariano; Luis Fernando Vidal Saccomani; Karina Giovanetti; André Del Negro; Luiz Paulo Kowalski; Ana Cristina Victorino Krepischi; Albina Altemani
Journal:  Braz J Otorhinolaryngol       Date:  2016-02-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.